Abstract
Coronary artery disease (CAD) is the leading cause of mortality in Western Societies and several developing countries. Recent evidence suggests that most detrimental clinical manifestations of CAD, such as acute coronary syndromes (ACS), are the outcome of inflammatory processes that lead to plaque formation and rupture and eventually to ischemia and potentially myocardial necrosis. Neither of the traditionally used biomarkers is thought to be the gold standard in detection of myocardial ischemia or necrosis. A biomarker that could detect quite early the ischemic myocardium as well as define the risk of a future event with high sensitivity and specificity is still lacking. Several biomarkers, implicated in the pathogenesis and clinical evolution of atherosclerosis, have emerged as potent biomarkers for early detection of myocardial ischemia. In the current review, we summarize recent evidence of the most promising biomarkers and discuss their potential role in clinical practice in patients suffering from ACSs.
Keywords: Biomarkers, atherosclerosis, ischemia, acute coronary syndrome, myocardial infarction, Coronary artery disease(CAD), clinical manifestations, syndromes, inflammation, myocardial ischemia
Current Medicinal Chemistry
Title:Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Volume: 19 Issue: 16
Author(s): D. Tousoulis, G. Hatzis, N. Papageorgiou, E. Androulakis, G. Bouras, A. Giolis, C. Bakogiannis, G. Siasos, G. Latsios, C. Antoniades and C. Stefanadis
Affiliation:
Keywords: Biomarkers, atherosclerosis, ischemia, acute coronary syndrome, myocardial infarction, Coronary artery disease(CAD), clinical manifestations, syndromes, inflammation, myocardial ischemia
Abstract: Coronary artery disease (CAD) is the leading cause of mortality in Western Societies and several developing countries. Recent evidence suggests that most detrimental clinical manifestations of CAD, such as acute coronary syndromes (ACS), are the outcome of inflammatory processes that lead to plaque formation and rupture and eventually to ischemia and potentially myocardial necrosis. Neither of the traditionally used biomarkers is thought to be the gold standard in detection of myocardial ischemia or necrosis. A biomarker that could detect quite early the ischemic myocardium as well as define the risk of a future event with high sensitivity and specificity is still lacking. Several biomarkers, implicated in the pathogenesis and clinical evolution of atherosclerosis, have emerged as potent biomarkers for early detection of myocardial ischemia. In the current review, we summarize recent evidence of the most promising biomarkers and discuss their potential role in clinical practice in patients suffering from ACSs.
Export Options
About this article
Cite this article as:
Tousoulis D., Hatzis G., Papageorgiou N., Androulakis E., Bouras G., Giolis A., Bakogiannis C., Siasos G., Latsios G., Antoniades C. and Stefanadis C., Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers, Current Medicinal Chemistry 2012; 19 (16) . https://dx.doi.org/10.2174/092986712800493011
DOI https://dx.doi.org/10.2174/092986712800493011 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurotoxicity by Synthetic Androgen Steroids: Oxidative Stress, Apoptosis, and Neuropathology: A Review
Current Neuropharmacology The role of NADPH Oxidase in Vascular Disease – Hypertension, Atherosclerosis & Stroke
Current Pharmaceutical Design S-nitrosation/Denitrosation in Cardiovascular Pathologies: Facts and Concepts for the Rational Design of S-nitrosothiols
Current Pharmaceutical Design Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry Ion Transporters in Brain Tumors
Current Medicinal Chemistry Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
Current Diabetes Reviews A Pilot Study to Assess Adenosine 5’-triphosphate Metabolism in Red Blood Cells as a Drug Target for Potential Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets The Universal Nature, Unequal Distribution and Antioxidant Functions of Melatonin and Its Derivatives
Mini-Reviews in Medicinal Chemistry Biomarkers for Diagnosing and Staging of Fabry Disease
Current Medicinal Chemistry Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design Positron Emission Tomography: Applications In Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry General or Local Anesthesia for TAVI? A Systematic Review of the Literature and Meta-Analysis
Current Pharmaceutical Design Ivabradine: Cardiovascular Effects
Recent Patents on Cardiovascular Drug Discovery Editorial (Hot Topic: Vascular Remodeling)
Current Vascular Pharmacology Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design MicroRNAs in Cardiovascular Therapeutics
Current Topics in Medicinal Chemistry Nitric Oxide Synthase Function in Exercise
Current Enzyme Inhibition Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets Quetiapine to Treat Agitation in Dementia: A Randomized, Double-Blind,Placebo-Controlled Study
Current Alzheimer Research